Key Highlights
- 1.04 is the negative consensus EPS estimate per the screener snapshot for Lifeward Ltd. (NASDAQ:LFWD), which is due to report third quarter 2026 results before the market opens on November 13, 2026.
- 6.6 million is the USD Revenue for the second quarter of 2026, up 16% from USD 5.7 million, led by AlterG at USD 4.1 million and ReWalk Personal at USD 2.5 million.
- 11.5 million is the USD GAAP net loss for the second quarter, or USD 4.12 per share, driven by a USD 6.9 million non-cash remeasurement, versus a non-GAAP net loss of USD 4.1 million.
- 16.35 million is the USD market Capitalization per the screener snapshot, a nano-cap level, while unrestricted cash was USD 9.4 million at June 30, 2026, with pro forma cash of about USD 11 million.
What Investors Expect From Lifeward Ltd. (NASDAQ:LFWD) on November 13, 2026
Lifeward Ltd. is listed to report third quarter 2026 results before the market opens (BMO) on November 13, 2026. The consensus estimate per the screener snapshot is a loss of USD 1.04 per share. Second quarter non-GAAP loss was USD 1.46 per share and GAAP loss was USD 4.12 per share, both after a 1-for-12 reverse split on February 24, 2026. Market capitalization per the screener snapshot is USD 16.35 million, a nano-cap level carrying high Volatility and liquidity risk.
The Rationale: Last Reported Quarter and Management Outlook for Lifeward Ltd. (NASDAQ:LFWD)
In the second quarter of 2026, revenue grew 16% to USD 6.6 million, gross Margin was 40.9% versus 43.9% because of tariffs, currency moves and a 4% revenue-sharing expense, and operating expenses were USD 6.9 million versus USD 9.1 million. Operating loss narrowed to USD 4.2 million from USD 6.6 million. No numerical 2026 guidance was found. The chief executive expects revenue momentum to continue in the second half, citing a strong pipeline, and an Ottobock Care pilot began in August 2026 to widen access to ReWalk Personal.
Valuation, Liquidity and Risks for Lifeward Ltd. (NASDAQ:LFWD)
Per the screener snapshot, the Market Value is USD 16.35 million. Cash rose to USD 9.4 million from USD 2.2 million at year-end after a financing of up to USD 11.2 million, of which about USD 5.6 million has been raised. Convertible notes were USD 4.4 million and financing liabilities USD 4.1 million, against total Assets of USD 35.0 million and Equity of USD 12.2 million. Weighted-average shares were 2,796,621. Risks include dilution, tariffs, executive turnover, with the finance chief leaving on September 30, 2026, and dependence on trial progress at the oral insulin program.
Where Things Stand
Where things stand: Lifeward Ltd. (NASDAQ:LFWD) reports third quarter 2026 results before the market opens on November 13, 2026, with a consensus EPS estimate of -1.04 and a market value of USD 16.35 million per the screener snapshot. The second quarter delivered revenue growth of 16% to USD 6.6 million and an operating loss of USD 4.2 million, while cash reached USD 9.4 million. Three directors stepped down on August 13, 2026, and an additional USD 5.6 million of growth capital is available if ReWalk sales rise 150% or the stock holds at USD 13.80 or higher for ten trading days. Investors will watch margins, cash burn and pipeline conversion. This article is informational and is not Investment advice.
_11_19_2026_19_19_13_574021.jpg)





Please wait processing your request...